As part of an investigation on further potential prognostic markers in this indication, the influence of BRAF mutations and MSI on metastatic spread and prognosis was analyzed within a large retrospective case series: BRAF-mutant tumors, particularly those harboring a V600E mutation, are associated with a significantly poorer overall survival (OS) than BRAF wild-type tumors (median 10.4 versus 34.7 months; hazard ratio [HR] = 10.66, p < 0.001), as well as with a higher rate of peritoneal and distant lymph node metastasis [12]. This evidence concerns the gene BRAF and metastatic malignant neoplasm in the lymph nodes.